Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer.

ABSTRACT:

Background

The acquisition of somatic mutations associated with the expansion of certain hematopoietic stem cells is known as clonal hematopoiesis (CH). Despite evidence of CH association with age-related pro-inflammatory diseases, little is known about its role in the response to antitumor immune modulatory therapies such as immune-checkpoint inhibition (ICI). In this report, we characterize the effect of CH on ICI objective response in non-small cell lung cancer (NSCLC).

Methods

We performed baseline blood-derived whole-exome sequencing of 1,281 patients with NSCLC from five anti-programmed death ligand-1 (PD-L1) trials (FIR, POPLAR, IMpower110, IMpower150, and IMpower131). Multivariable logistic regression adjusting for age, sex, and smoking history was used to model the

SUBMITTER: Chat V 

PROVIDER: S-EPMC12458721 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature